PharmaMar's cancer drug candidate PM1183, or lurbinectedin, has been licensed to Specialized Therapeutics Asia for marketing in 12 Southeast Asian nations as well as New Zealand and Australia. Under the terms of the deal, PharmaMar will get an upfront payment and is eligible to receive payments tied to regulatory and sales milestones for the RNA polymerase II inhibitor.
PharmaMar cancer drug candidate licensed in Australia, Southeast Asia
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.